Modified virus takes on Hard-to-Treat tumors in early trial
NCT ID NCT07262164
First seen Jan 11, 2026 · Last updated May 13, 2026 · Updated 24 times
Summary
This early-phase study tests a new drug called VG2062, which is a modified virus designed to attack cancer cells. It is for people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety and find the best dose for future studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
No. 67, Huayuan Road, Langfang Economic and Technological Development Zone, Hebei Province
RECRUITINGHebei, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.